Profile data is unavailable for this security.
About the company
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
- Revenue in USD (TTM)0.00
- Net income in USD-29.69m
- Incorporated2009
- Employees10.00
- LocationAtossa Therapeutics Inc107 Spring StSEATTLE 98104-1005United StatesUSA
- Phone+1 (206) 588-0256
- Fax+1 (302) 636-5454
- Websitehttps://atossatherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Quantum-Si Inc | 1.29m | -91.82m | 164.51m | 159.00 | -- | 0.6483 | -- | 128.02 | -0.6482 | -0.6482 | 0.0091 | 1.79 | 0.004 | 0.196 | 7.93 | 8,081.76 | -28.67 | -- | -29.50 | -- | 49.26 | -- | -7,145.76 | -- | 30.03 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
TriSalus Life Sciences Inc | 21.98m | -68.07m | 166.54m | 112.00 | -- | -- | -- | 7.58 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
Achieve Life Sciences Inc | 0.00 | -27.32m | 166.90m | 22.00 | -- | 3.37 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
Syros Pharmaceuticals Inc | 6.98m | -144.49m | 174.54m | 68.00 | -- | 11.59 | -- | 25.00 | -5.01 | -5.01 | 0.2244 | 0.5633 | 0.0411 | -- | -- | 102,661.80 | -84.98 | -54.44 | -103.51 | -64.32 | -- | -- | -2,069.80 | -772.82 | -- | -- | 0.7332 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
Atossa Therapeutics Inc | 0.00 | -29.69m | 174.80m | 10.00 | -- | 2.03 | -- | -- | -0.2359 | -0.2359 | 0.00 | 0.6833 | 0.00 | -- | -- | 0.00 | -28.65 | -29.97 | -29.84 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
Puma Biotechnology Inc | 226.63m | 15.38m | 176.07m | 185.00 | 11.34 | 3.45 | 6.54 | 0.7769 | 0.3219 | 0.3219 | 4.74 | 1.06 | 1.10 | 10.95 | 8.13 | 1,225,016.00 | 7.49 | -12.21 | 11.65 | -20.53 | 73.44 | 78.78 | 6.78 | -11.79 | 1.38 | 2.57 | 0.6624 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
Skye Bioscience Inc | 0.00 | -37.50m | 177.11m | 11.00 | -- | 2.24 | -- | -- | -4.50 | -4.50 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -75.43 | -232.67 | -101.00 | -- | -- | -- | -- | -- | -- | -46.11 | 0.0552 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
INmune Bio Inc | 131.00k | -34.50m | 179.62m | 11.00 | -- | 5.62 | -- | 1,371.18 | -1.92 | -1.92 | 0.0073 | 1.62 | 0.0022 | -- | 0.0535 | 11,909.09 | -57.11 | -37.82 | -74.12 | -41.86 | -- | -- | -26,333.59 | -14,901.03 | -- | -16.97 | 0.2044 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
Fennec Pharmaceuticals Inc | 44.95m | 2.84m | 181.70m | 36.00 | 181.84 | 59.80 | 63.89 | 4.04 | 0.0366 | 0.0366 | 1.62 | 0.1112 | 0.9878 | 1.15 | 7.52 | -- | 6.25 | -73.43 | 7.37 | -84.32 | 96.19 | -- | 6.33 | -383.28 | 6.72 | 1.84 | 0.9087 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
Rigel Pharmaceuticals Inc | 120.35m | -19.80m | 181.73m | 147.00 | -- | -- | -- | 1.51 | -1.13 | -1.13 | 6.90 | -1.81 | 0.9623 | 0.9241 | 4.23 | 818,680.30 | -15.83 | -28.82 | -30.14 | -47.26 | 93.22 | 97.88 | -16.45 | -35.76 | 1.17 | -2.91 | 2.13 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
Adverum Biotechnologies Inc | 0.00 | -112.90m | 182.25m | 121.00 | -- | 0.9997 | -- | -- | -10.23 | -10.23 | 0.00 | 8.78 | 0.00 | -- | -- | 0.00 | -41.55 | -36.39 | -47.50 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
G1 Therapeutics Inc | 84.04m | -30.59m | 184.03m | 100.00 | -- | 6.63 | -- | 2.19 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
Acumen Pharmaceuticals Inc | 0.00 | -55.94m | 184.44m | 51.00 | -- | 0.7039 | -- | -- | -1.05 | -1.05 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | -22.89 | -- | -23.72 | -- | -- | -- | -- | -- | -- | -- | 0.1034 | -- | -- | -- | -22.20 | -- | -- | -- |
Rani Therapeutics Holdings Inc | 0.00 | -33.08m | 186.56m | 140.00 | -- | 24.12 | -- | -- | -1.29 | -1.29 | 0.00 | 0.1534 | 0.00 | -- | -- | 0.00 | -87.80 | -- | -140.92 | -- | -- | -- | -- | -- | -- | -28.75 | 0.6695 | -- | -- | -- | -11.06 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 5.71m | 4.54% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.30m | 1.83% |
Laurion Capital Management LPas of 31 Mar 2024 | 2.23m | 1.77% |
Renaissance Technologies LLCas of 31 Mar 2024 | 1.39m | 1.10% |
Geode Capital Management LLCas of 31 Mar 2024 | 1.21m | 0.96% |
Millennium Management LLCas of 31 Mar 2024 | 1.01m | 0.81% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 739.81k | 0.59% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 628.55k | 0.50% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 493.57k | 0.39% |
HRT Financial LLCas of 31 Mar 2024 | 291.42k | 0.23% |